Navigation Links
Evotec Starts Phase II in Smoking Cessation with EVT 302
Date:2/28/2008

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B).

This double-blind, three-way cross-over study is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes in 90 smokers. Smokers will receive a single dose of EVT 302, nicotine, and placebo in a random order. The effect of EVT 302 on craving when combined with nicotine replacement therapy will be assessed as a secondary outcome. In addition, safety and tolerability as well as additional outcome parameters relating to exposure and MAO-B inhibition will be investigated. The results are expected to be reported in the third quarter of 2008.

Dr John Kemp, Chief Research & Development Officer at Evotec, commented: "Evotec is extremely proud to have progressed its second drug candidate into Phase II clinical trials. I am extremely pleased with the safety and tolerability profile of EVT 302 in young and elderly subjects emerging from Phase I studies and look forward to continued progress with this compound."

This is one of two Phase II studies planned to be initiated in 2008 as part of the clinical development program of EVT 302 in smoking cessation. The second study to access the impact of EVT 302 on the quit rate of heavy smokers withdrawing from cigarettes is expected to start in mid 2008.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business comb
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 At the ... has granted a 60-day extension for the public comment ... Special Rule for Model Aircraft established by Congress as ... 2012. The 60-day extension establishes the new deadline for ... States Department of Transportation/FAA notice published in the Federal ...
(Date:7/24/2014)... , July 24, 2014  Now available is a ... Rehealth Regenerative Therapies , located in ... physically active people a new health option: stem ... of age, countless patients suffer from joint and muscle ... as muscle tears, torn rotator cuff, tennis elbow, and ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2
... MONROVIA, Calif., June 9 STAAR Surgical Company (Nasdaq: ... marketer of minimally invasive ophthalmic products, today announced that ... Preloaded Hydrophobic Acrylic Injector for use in minimally invasive ... Surgical to market this foldable intraocular (IOL) KS-X lens ...
... Mass., June 8 Caliper Life Sciences, Inc. (Nasdaq: ... Customer and Investor Open House entitled, "Innovation for Experimentation" to ... The company will webcast the Investor Breakout Session from 2:30 ... of the conference will feature presentations by Kevin Hrusovsky, President ...
... BEIJING, June 8 /PRNewswire-Asia/ -- Sinovac Biotech ... of vaccines in China, announced today that it,begins the production of ... from US CDC and was delivered to the company on June ... President and CEO of Sinovac, commented, ,In,the midst of a global ...
Cached Biology Technology:STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 2STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 3STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 4Caliper Life Sciences to Webcast Investor Session of Open House 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3
(Date:7/24/2014)... that characterize sustainable university and college programs designed ... teachers. Specifically, one or more faculty members who ... with institutional motivation and commitment can ensure that ... Math (STEM) teacher shortages are especially acute in ... institutions seeking to increase the number of STEM ...
(Date:7/24/2014)... June 24, 2014 Some sticky research out of ... against a certain species of toxic grass fungus: moose ... month,s Biology Letters , "Ungulate saliva inhibits a ... applied to red fescue grass (which hosts a fungus ... in slower fungus growth and less toxicity. , "Plants ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva University ... Foundation for Parkinson,s Research to translate a basic science ... discovery project will test chemical compounds on a newly ... that acts on an underlying cause of the disease. ... people manage their symptoms, we are eager to stop ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... some have argued, can be reversed with a large-scale ... liquefied sulfur dioxide in the stratosphere or building tens ... to filter out carbon dioxide. ... of Atmospheric and Oceanic Sciences and a member and ...
... biological tit for tat may hold clues to improving ... type 1 diabetes, according to a Medical College of ... attacks insulin-producing cells causing high blood glucose levels that ... an immunologist in the MCG Center for Biotechnology and ...
... Ind. - Purdue University researchers found a mechanism that ... how to keep that switch turned on may be ... Nicholas Carpita, a professor of botany and plant pathology, ... in plant development by shutting off genes involved in ...
Cached Biology News:No quick or easy technological fix for climate change, researchers say 2No quick or easy technological fix for climate change, researchers say 3No quick or easy technological fix for climate change, researchers say 4High blood sugar's impact on immune system holds clues to improving islet cell transplants 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 3Researchers find nature's shut-off switch for cellulose production 2